成都欧林生物科技股份有限公司 高级管理人员减持计划完成暨减持股份结果公告

Summary of Key Points Core Viewpoint - The company announced the completion of a share reduction plan by its Vice President and Chief Financial Officer, which involved the sale of shares amounting to 0.0317% of the total share capital [1][4]. Group 1: Shareholding and Reduction Plan - Before the reduction plan, the Vice President, Mr. Tan Yong, held 571,440 shares, representing 0.14% of the total share capital, with 515,440 shares being tradable and 56,000 shares being restricted [1]. - The reduction plan was disclosed on September 5, 2025, with Mr. Tan planning to sell up to 128,860 shares within three months following the announcement [1]. - The actual reduction occurred between September 29, 2025, and October 31, 2025, where Mr. Tan sold 128,860 shares, leaving him with 442,580 shares, which is 0.1090% of the total share capital [1][4]. Group 2: Implementation Results - The reduction plan was fully implemented as per the disclosed plan, with no discrepancies between the planned and actual reductions [4]. - There were no early terminations of the reduction plan, confirming that it was executed as intended [4].